← AI Intelligence Hub

Clinical & Diagnostics

6 Health Systems Enhancing Care Delivery with Ambient AI Scribes

Executive BriefReal-world deployments prove ambient AI scribes are delivering measurable time savings for clinicians — with Cooper University Healthcare saving doctors more than one hour of documentation daily, a milestone that directly translates to more time with patients.

Across five academic medical centers, AI ambient scribes cut total EHR time by 13.4 minutes and documentation time by 16 minutes per encounter. Cooper University Healthcare's deployment of Microsoft Dragon Copilot saved 4.15 minutes per patient; at typical daily patient volumes, that compounds to 60+ minutes reclaimed per clinician per day. The AHA profiled six health systems — including major academic medical centers — now running ambient scribe programs in production.

IKS Health Debuts First-of-Its-Kind Agentic AI Platform to Automate and Personalize Patient Engagement

Executive BriefIKS Health launched MyCareHub, an agentic AI patient-engagement platform that can independently navigate complex care journeys — scheduling, follow-up, reminders, and personalized outreach — without requiring clinician intervention at each step.

MyCareHub runs on a multi-agent behavioral algorithm described as "active, aware, and constant," orchestrating patient interactions across the full care cycle. The platform integrates natively with Epic and is already listed in the Epic App Orchard / Connection Hub, enabling rapid deployment for Epic-using health systems. The architecture self-orchestrates — agents hand off between tasks without human routing — distinguishing it from single-workflow chatbots.

How Amazon Connect Health Brings Agentic AI to the Point of Care

Executive BriefAmazon's healthcare contact center platform now embeds agentic AI directly into patient-facing care workflows, enabling automated triage, appointment coordination, and care-gap outreach at the moment patients are seeking help — rather than days later.

Amazon Connect Health leverages AWS Bedrock-powered agents to handle multi-turn clinical support conversations, integrating with EHR systems via FHIR APIs for real-time patient data retrieval. The solution supports voice and messaging channels and routes complex escalations to human coordinators with full context transfer, reducing average handle time and enabling 24/7 clinical support coverage at scale.

Research & Science

Clinical AI Has Boomed. A New Stanford-Harvard Report Shows What Actually Holds Up in Practice.

Executive BriefThe first comprehensive State of Clinical AI report separates proven clinical AI from hype — identifying which applications genuinely improve care once deployed in real hospitals and which ones collapse under real-world conditions of bias, workflow friction, and data variability.

Released by the ARISE network (Stanford-Harvard collaborative), the 2026 report reviewed the most influential clinical AI studies published in 2025 through a deployment lens — asking not just whether models work in controlled trials but whether they hold performance post-deployment. Key findings: early deterioration detection and radiology-assist tools show the strongest real-world evidence; clinical chatbots and autonomous diagnostic agents show the widest gap between trial and practice performance. The report flags underexamined risks in patient-facing AI as the field's most urgent gap.

The $6M AI Drug That Beat a $100M Development Process: Insilico's IPF Candidate Completes Phase IIa

Executive BriefInsilico Medicine's INS018_055 — the first fully AI-conceived and AI-designed drug — successfully completed Phase IIa clinical trials for idiopathic pulmonary fibrosis, a lung-scarring disease with limited treatment options. The discovery cost roughly $6 million and took 18 months, compared to the typical $100M+ and 5+ year conventional timeline.

INS018_055 was designed end-to-end using Insilico's Pharma.AI platform, combining generative chemistry models for molecule design with a proprietary target identification engine (PandaOmics) trained on multi-omics datasets. The compound achieved Phase IIa efficacy endpoints, with the AI-driven process compressing target identification, lead optimization, and ADMET profiling into a single integrated pipeline. The cost comparison — ~$6M computational vs. $100M+ conventional — is drawing significant attention from pharma R&D leadership worldwide.

Merck and Mayo Clinic Announce AI-Enabled Drug Discovery and Precision Medicine Collaboration

Executive BriefTwo of the most powerful names in medicine — Merck and Mayo Clinic — have formally joined forces to apply AI and multimodal clinical data to drug discovery, representing one of the most significant pharma-health system AI partnerships to date.

The collaboration integrates Mayo Clinic's clinical and genomic datasets with Merck's AI-enabled virtual cell technologies and advanced analytics infrastructure. The partnership targets drug target identification, biomarker discovery, and patient stratification for clinical trials — using longitudinal real-world data from Mayo's massive patient population to ground Merck's computational models in clinically validated signal rather than synthetic or siloed research data.

Deep Learning Bridges Pathology and Radiology for a New Era of AI-Assisted Medical Imaging

Executive BriefA new class of deep learning systems is breaking down the historical separation between radiology and pathology — enabling simultaneous interpretation of imaging scans and tissue slides that yields more accurate cancer diagnoses than either modality alone.

The models use dual-stream convolutional neural networks (CNNs) combined with Transformer-based cross-attention layers to fuse features extracted from radiology images (CT, MRI) and digital pathology slides (H&E, IHC). On multi-cancer benchmarks, fused models outperformed single-modality networks by 7–12% on AUC, with the strongest gains in cases where radiology and pathology findings were discordant — exactly the complex cases that most strain human diagnostic capacity. Researchers note that integrated reporting workflows remain the primary clinical adoption barrier.

Policy & Regulation

FDA Announces Sweeping Rollback of Oversight for AI-Enabled Devices and Wearables

Executive BriefThe FDA under Commissioner Marty Makary moved to dramatically loosen oversight of clinical decision support software and consumer health wearables — a major deregulatory shift that accelerates AI product launches but raises concerns about patient safety guardrails.

Two January 2026 FDA guidance documents expanded the definition of "general wellness" devices to include blood pressure, heart rate, and blood glucose monitoring wearables, removing them from the 510(k) pathway. A parallel guidance softened requirements for clinical decision support software, allowing products to enter the market without FDA review if they satisfy the agency's non-device CDS criteria. The changes are projected to affect hundreds of AI-enabled products currently in regulatory limbo. Most high-risk AI medical device obligations still take effect in August 2026, with full compliance required by August 2027.

Aidoc Wins FDA Clearance for Comprehensive Foundation Model AI — 14 Indications, One Model

Executive BriefAidoc received FDA clearance for 11 new clinical indications powered by a single foundation AI model — the first FDA clearance of double-digit acute findings from a unified architecture — consolidating what previously required multiple separate AI tools into one integrated triage system.

The clearance covers Aidoc's CARE (Clinical AI Radiology Engine) foundation model, which runs 11 newly cleared acute indications alongside 3 previously cleared ones — including hemorrhage, pulmonary embolism, pneumothorax, and aortic dissection — from a single shared model rather than siloed per-indication algorithms. The foundation model approach allows continuous learning across indication classes and reduces integration overhead for health system deployments. This represents a significant architectural shift in how FDA AI approvals are structured.

TEFCA — America's National Interoperability Network — Reaches 500 Million Health Records Exchanged

Executive BriefThe federal government's national health data exchange network TEFCA crossed the 500-million-record milestone, signaling that the infrastructure for AI to access longitudinal patient data at population scale is now operationally real — not theoretical.

TEFCA (Trusted Exchange Framework and Common Agreement) operates through Qualified Health Information Networks (QHINs) using FHIR R4-based APIs to route patient data across participating organizations. The 500M-record exchange volume demonstrates sufficient network density for AI applications requiring multi-system longitudinal records — particularly care coordination agents, population health models, and real-world evidence generation. HHS credited AI-assisted data normalization tools as a contributor to TEFCA's accelerated adoption curve in 2025–2026.

Industry & Business

UnitedHealth Group Is Making a $3 Billion Bet on AI — What It Means for Patients

Executive BriefUnitedHealth Group — the largest health insurer in the U.S. — is deploying AI at a scale few organizations can match, with 22,000 software engineers and a $3B investment commitment. The patient-facing question is whether this investment reduces friction and improves care or primarily optimizes for cost and claim denial.

More than 80% of UHG's 22,000 software engineers now use AI to write code or build autonomous agents. The company's AI stack spans prior authorization automation, predictive health risk scoring across its Optum data assets (covering records for ~150M Americans), clinical decision support embedded in the UHC insurance product, and care coordination agents through Optum Health. STAT's reporting explores how AI-driven prior auth tools affect approval rates and denial patterns — a key regulatory flashpoint as CMS moves toward mandating automated prior authorization interoperability by 2027.

Digital Health Funding Hits $4B in Q1 2026 — Strongest Quarter Since the Pandemic Peak

Executive BriefDigital health investment roared back in Q1 2026, reaching $4 billion — $1B above Q1 2025 and the best first quarter since 2021's funding frenzy — driven almost entirely by AI-enabled companies commanding premium valuations and mega-round deal sizes.

Q1 2026 saw $5.34B deployed across 105 deals with 18 mega-rounds (greater than or equal to $100M) dominating capital deployment. AI-enabled health startups captured 62%+ of total digital health VC and commanded an 83% valuation premium over non-AI peers. Top funded categories: non-clinical workflow automation, clinical workflow tools, and data infrastructure. Ambient scribing, prior authorization automation, and population health AI attracted the highest deal counts. Galen Growth data shows the U.S. accounted for the dominant share of global digital health investment, widening the gap with European and Asian markets.

Jimini Health Raises $17M Seed to Launch AI Mental Health Chatbot Sage with Health Systems

Executive BriefMental health startup Jimini Health raised $17M to scale Sage, an AI chatbot that maintains continuous therapeutic engagement with patients between human therapy sessions — targeting the massive care gap where patients may wait weeks between appointments with no clinical touchpoint.

Sage is designed to operate under clinician supervision — it engages patients continuously but generates structured session summaries and escalation flags for the treating therapist rather than operating autonomously. The product targets large behavioral health organizations and health system-employed mental health programs as its distribution channel, bypassing the fragmented individual practice market. The $17M seed is notable for its size at such an early stage, reflecting the premium investors are placing on behavioral health AI with clinical oversight architecture built in from inception.

Qualified Health Raises $125M Series B to Accelerate Generative AI Deployment Across Health Systems

Executive BriefQualified Health closed a $125M Series B led by New Enterprise Associates to build out generative AI capabilities for health systems — one of the largest pure-play health system AI platform rounds of 2026, signaling strong institutional confidence in enterprise AI integration as the next growth frontier.

Qualified Health's platform targets multi-modality generative AI deployment within large health systems — spanning clinical documentation, care gap identification, patient communication, and revenue cycle automation. The Series B will fund model fine-tuning on proprietary health system data, EHR integration engineering (primarily Epic and Oracle Health), and compliance infrastructure for HIPAA-covered AI deployments. NEA's lead reflects the firm's thesis that enterprise health system AI is entering a high-growth consolidation phase where platform players will outperform point solutions.

Social Buzz

1 in 4 Americans Now Uses AI for Healthcare Advice — Often Instead of Seeing a Doctor

Executive BriefA new West Health-Gallup survey finds 25% of Americans have used AI for medical advice — and that many are bypassing physicians entirely, not just supplementing their visits. The dominant driver: speed. People want answers now, and they're getting them from AI whether clinicians like it or not.

The nationally representative survey found that roughly 60% of AI healthcare users consulted AI before or after a doctor visit as a supplement, but a significant minority used it as a direct substitute for clinical care. Speed was cited as the primary reason by the largest respondent segment, followed by cost and access barriers. The data tracks alongside a parallel Gallup poll showing AI healthcare tool use rose from near-zero in 2022 to 25% penetration in early 2026 — a faster consumer adoption curve than telehealth saw in its first decade. The findings are generating intense LinkedIn commentary from physicians debating accuracy, liability, and the implications for clinical relationships.

Trust in Healthcare AI Is Dropping — Only 42% of Americans Now Open to AI-Assisted Care, Down from 52%

Executive BriefDespite explosive AI adoption in hospitals and growing consumer use of medical chatbots, public trust in AI-assisted healthcare has fallen sharply — dropping 10 percentage points in two years. The trust gap is becoming the healthcare AI industry's most underappreciated risk.

Ohio State University Wexner Medical Center's survey found willingness to accept AI as part of care fell from 52% in 2024 to 42% in 2026, a statistically significant drop. Concerns cluster around three themes: lack of transparency in how AI makes decisions, fears about data privacy and insurance implications, and discomfort with AI replacing the physician relationship. The findings are driving a counternarrative on LinkedIn and X, where clinicians and health IT leaders debate whether the industry is deploying AI faster than it's building the patient trust infrastructure needed to sustain it — generating significant engagement in healthcare professional communities this week.

AI in the Mental Health Workforce: Fear, Pushback — and Real Enthusiasm Among Therapists

Executive BriefNPR's deep-dive into AI adoption across mental health practices finds a workforce divided: some therapists are saving 10–15 hours per week on documentation and welcoming more time with patients; others fear AI is eroding the uniquely human therapeutic relationship that makes mental health care work at all.

The report profiles large health systems and independent therapists across the adoption spectrum. Administrative AI — scheduling, billing, intake, insurance verification — has penetrated broadly with minimal resistance. Clinical AI use remains limited: Dr. John Torous, director of digital psychiatry at Beth Israel Deaconess, told NPR "we're not seeing a lot of clinical use of AI today" despite widespread administrative adoption. Key infrastructure barriers: most small practices and community mental health centers lack the IT staff and budget to evaluate, procure, and maintain clinical AI platforms. The story is driving high engagement in mental health professional communities on LinkedIn and Reddit's r/therapists, where frontline practitioners are sharing firsthand experiences.